meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
Tislelizumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs docetaxel
All patients
Age < 65y (younger)
Age > 65y
cell type, non squamous cell
cell type, squamous cell
ECOG 0
ECOG 1
EGFR mutant
Gender, female
Gender, male
metastasis (brain) NO
metastasis (brain) YES
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC)
PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
smoker (current or former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
SAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pyrexia AE (grade 3-4)
Stomatitis AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS)
mNSCLC - L2 - all population
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population
versus docetaxel
atezolizumab alone vs. docetaxel
2
statistically conclusive
-19%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open